Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Chimeric antigen receptor, or CAR T-cell therapy, is a new form of immunotherapy that uses specially altered T cells to more specifically target cancer cells. The immune system is made up of specific cells and organs that protect the body from infection
and cancer. Among these are T cells, which hunt down and destroy abnormal cells, including cancer cells. Sometimes, cancer cells find ways to evade the immune system; so, the immune system needs to be retrained to recognize and attack cancer cells.
CAR T-cell therapy is one innovative approach to program the immune system to attack cancer.
After a sample of a patient's T cells has been collected from the blood, the cells are re-engineered so they sprout special structures called chimeric antigen receptors (CARs) on their surface. When these CAR T cells are reinjected into the patient, the
receptors may help the T cells identify and attack cancer cells throughout the body.
Currently, CAR T-cell therapy is FDA-approved as the standard of care for some forms of relapsed or refractory non-Hodgkin lymphoma, multiple myeloma, and pediatric relapsed acute lymphoblastic leukemia (ALL), and is available through clinical trials for other forms of blood cancer.
CAR T-Cell Therapy: How Does It Work?CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells – white blood cells that help protect the body from disease.
Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program, highlighted key CAR T-cell study results from the 2018 ASH Annual Meeting: Longer-term follow-up of CAR T in non-Hodgkin lymphoma; data of CAR T in the real-world vs. clinical trial setting; combination therapy with CAR T; and allogeneic CAR T.
Contact Information for CAR T-Cell Therapy
For more information about CAR T-cell therapy, please call 877-801-CART (2278).
Pediatric CAR T-Cell Therapy
Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Dr. Caron Jacobson on CAR T-Cell Therapy DataCaron Jacobson, MD, summarized CAR T studies from the 2017 ASH Annual Meeting on the promising, long-term data presented on CAR T-cell therapy for non-Hodgkin lymphoma, multiple myeloma, and acute lymphoblastic leukemia.